Overview

An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)

Status:
Active, not recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
A prospective, open-label, phase 2a study, to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of multiple doses of Cannabidiol (CBD) in participants Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)
Phase:
Phase 2
Details
Lead Sponsor:
Kalytera Therapeutics Israel, Ltd.